Cenix is an industry leader in performing RNAi-based Target Discovery screens, Target Validation studies, and Drug Mode of Action analyses in transformed or primary cell models.
Since 1999, our well-established core capabilities in high-throughput siRNA library screening together with fluorescent reader-based and high-content microscopy-based assays have yielded optimized protocols in a broad and ever-growing collection of cultured cell models, covering a wide range of disease fields including oncology, cardiovascular, metabolic, neurological and infectious diseases.